Behavior, Environment And Treatments for Covid-19 (BEAT19)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04321811 |
Recruitment Status :
Completed
First Posted : March 25, 2020
Last Update Posted : July 14, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background: During the current COVID-19 pandemic there is urgent need for information about the natural history of the infection in non-hospitalized patients, including the severity and duration of symptoms, and outcome from early in the infection, among different subgroups of patients. In addition, a large, real-world data registry can provide information about how different concomitant medications may differentially affect symptoms among patient subgroups. Such information can be invaluable for clinicians managing chronic diseases during this pandemic, as well as identify interventions undertaken in a naturalistic setting that have differential effects. Such factors may include patient diet, over the counter or prescription medications, and herbal and alternative treatments, among others. Identifying the natural disease history in patients from different demographic and disease subgroups will be important for identifying at-risk patients and effectiveness of interventions undertaken in the community.
Objectives: The purpose of this study is to understand at the population level the symptomatic course of known or suspected COVID-19 patients while sheltering-in-place or under quarantine. Symptoms will be measured using a daily report derived from the CTCAE-PRO as well as free response. Outcomes will be assessed based on the duration and severity of infection, hospitalization, lost-to-follow-up, or death. As a patient-centric registry, patients themselves may propose, suggest, and/or submit evidence or ideas for relevant collection.
Condition or disease | Intervention/treatment |
---|---|
Coronavirus | Other: Observation of patients with known, suspected, or at risk for COVID-19 infection |

Study Type : | Observational [Patient Registry] |
Actual Enrollment : | 5000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 1 Year |
Official Title: | A PATIENT-CENTRIC OUTCOMES REGISTRY OF PATIENTS WITH KNOWN OR SUSPECTED NOVEL CORONAVIRUS INFECTION SARS-COV-2 (COVID-19) |
Actual Study Start Date : | March 21, 2020 |
Actual Primary Completion Date : | February 9, 2021 |
Actual Study Completion Date : | March 20, 2021 |

Group/Cohort | Intervention/treatment |
---|---|
Participants
Adult men and women currently in the United States and willing to provide written informed consent and:
|
Other: Observation of patients with known, suspected, or at risk for COVID-19 infection
Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments. |
- Define Natural Symptom Course [ Time Frame: Cumulative symptom score from first onset of symptoms to resolution of symptoms (realistic timeframe of 14 days) ]
Daily survey of symptoms known or reported to be associated with COVID-19 infection based including:
Headache, Sore throat, Runny nose, Stuffy nose, Gritty/itch eyes, Watery eyes, Nausea, Vomiting, Diarrhea, Sneezing, Coughing, Shortness of breath, Difficulty breathing, Pain or pressure in your chest, Fever, Chills, Body aches, Fatigue, or other issues. Symptoms are rated by participants on a scale of none, mild, moderate, severe, or very severe.
- Time to Hospitalization [ Time Frame: Realistic timeframe of 14 days ]Time (in days) from onset of symptoms to hospitalization
- Time to Symptomatic Recovery [ Time Frame: Realistic timeframe of 14 days ]Time (in days) from onset of symptoms to resolution of symptoms

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- People who are feeling sick and have tested positive for COVID-19
- People who are feeling sick but have not tested positive for COVID-19
- People who are not feeling sick but want to participate
Exclusion Criteria:
• People who are unwilling or unable to provide informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04321811
United States, California | |
BEAT19.org | |
San Francisco, California, United States, 94022 |
Principal Investigator: | Mark Shapiro | xCures |
Responsible Party: | xCures |
ClinicalTrials.gov Identifier: | NCT04321811 |
Other Study ID Numbers: |
XC-PCOR-COVID19 |
First Posted: | March 25, 2020 Key Record Dates |
Last Update Posted: | July 14, 2022 |
Last Verified: | July 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | De-identified datasets will be made available to qualified researchers in accordance with the study protocol. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Coronavirus COVID19 SARS-CoV-2 COVID-19 |
COVID-19 Coronavirus Infections Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia |
Virus Diseases Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |